The analysis of the area under ROC and precision-recall curve conducted for all potential circulatory biomarkers confirmed the discriminatory diagnostic power of insulin as MetS risk predictor with good AUC and AUPRC outcomes. This evidence concerns the gene INS and metabolic syndrome.